Exon 20 insertion has been reported to be the most common HER2-activating alteration in NSCLC, which tends to affect the ATP-binding pocket of the HER2 receptor, leading to steric hindrance against conventional HER2-targeted tyrosine kinase inhibitors (TKIs) [1, 5]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.